fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Enzalutamide

All products: not a benefit

Apo-Enzalutamide · DIN 02562677 · 40 mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Xtandi; DOSAGE FORM/ STRENGTH: 40 mg capsule — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Updated: December 1, 2021 Initiation criteria for metastatic castration sensitive prostate cancer (mCSPC): For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on technetium-99m bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Castration sensitive as defined by the patient being treatment naïve to an ADT OR ADT initiated within the prior 6 months before start of therapy with enzalutamide OR ADT used in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more prior to start of enzalutamide; AND 4. Has not experienced disease progression with another an androgen receptor axis targeted therapy (ARAT) for castration sensitive prostate cancer; AND 5. Patient has good performance status. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) The following baseline levels are to be provided with the initial application; i) Number of metastatic lesions on bone scan and in soft tissues ii) Testosterone level iii) Baseline (pre-treatment) PSA level iv) Pre-treatment Gleason score (optional) 305 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have previously progressed on a second-generation androgen receptor inhibitor (e.g. apalutamide, enzalutamide, darolutamide) for prostate cancer will not be eligible for enzalutamide in mCSPC. The Ministry will fund only one of enzalutamide or apalutamide in patients with mCSPC. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Patients who progress on treatment with enzalutamide or apalutamide mCSPC will not be eligible for enzalutamide in the metastatic castration resistant setting. 4. Patients who are currently on a treatment regimen with an androgen receptor axis targeted therapy (e.g. abiraterone or a second-generation androgen receptor inhibitor) for prostate cancer, must meet the initiation criteria if they wish to switch to publicly funded enzalutamide for mCSPC. 5. Time limited funding consideration will be provided on a case-by case basis for those patients who are using docetaxel in combination with ADT as long as there has been no progression and the treatment regimen has not been used for more than 6 months. Approved Dosage: 160 mg administered orally once daily. Renewal Criteria: Renewals will be considered in patients until disease progression (i.e. PSA elevation in addition to radiographic disease progression, or PSA progression in addition to clinical symptoms associated with cancer progression), development of castration resistant disease, or experiencing unacceptable toxicity while on enzalutamide. Exclusion Criteria: (Patients meeting any of the following will not be funded.) 1. Patients who have previously experienced disease progression on enzalutamide or another ARI used in the setting of prostate cancer. 2. Patients who have risk factors for seizures 3. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 306 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation Criteria for high risk non-metastatic castration resistant prostate cancer (nmCRPC): For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) in patients who meet all the following criteria: 1. Patient using Xtandi in combination with androgen deprivation therapy (ADT); AND 2. Has no detectable distant metastases as determined by CT, MRI, or technetium-99m bone scan; AND 3. Patient has castration resistant disease based on meeting all the following indicia observed while on continuous ADT treatment or post orchiectomy: • Castrate serum testosterone levels: AND • Biochemical progression defined as Three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL; and 4. Patient is at high risk for developing metastatic disease based on a Prostate-specific antigen doubling time (PSADT) of less than or equal to 10 months during continuous ADT. 5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2. Approval Duration: 1 year Exclusion Criteria: 1. The patient received prior chemotherapy for the treatment of prostate cancer, unless it was in the adjuvant or neoadjuvant setting. 2. The patient has previously experienced disease progression on apalutamide or darolutamide used for prostate cancer. 3. The patient has risk factors for seizures. 307 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) Approved Dosage: 160mg administered orally once daily Notes: 1. The Ministry will fund only one second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, or enzalutamide) in patients with nmCRPC. 2. Patients who have progressed on enzalutamide in nmCRPC will not be eligible for enzalutamide in metastatic castration resistant prostate cancer (mCRPC). 3. Requests for enzalutamide in patients who have initiated another ARI therapy in the nmCRPC setting and who have not experienced disease progression will be considered on a case-by-case basis. Renewal Criteria: Renewals will be considered in patients without evidence of radiographic disease progression or unacceptable toxicity while on enzalutamide therapy. Approval Duration: 1 year 308 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation criteria for metastatic castration resistant prostate cancer (mCRPC): For the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients meeting the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on a bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Patient has castration resistant disease based on meeting the following indicia observed while on continuous ADT treatment or post orchiectomy: 4. Castrate serum testosterone levels; AND 5. Biochemical progression defined as three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL AND/OR radiographic progression of new or pre-existing disease as determined by the detection of 2 or more lesions on bone scan or presence of new soft tissue lesions by RECIST criteria; AND 6. Patient has progressed on a docetaxel-based chemotherapy OR Patient is using enzalutamide pre-docetaxel for metastatic castration resistant prostate cancer and has not previously experienced disease progression on enzalutamide or another second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide,) used for prostate cancer OR Patient is using enzalutamide pre-docetaxel for mCRPC and has not previously experienced disease progression on abiraterone used in mCRPC sequenced immediately prior to enzalutamide; AND 7. Patient has good performance status defined as an Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 2. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) 309 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have progressed on treatment with second generation androgen receptor inhibitors (e.g. apalutamide, enzalutamide, darolutamide) used in prior stages of prostate cancer will not be eligible for enzalutamide in the metastatic castration resistant setting. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Requests for enzalutamide in patients who initiated abiraterone therapy and who have not had disease progression while on abiraterone will be considered on a case-by- case basis. Exclusion criteria: (Patients meeting any of the following will not be funded) 1. The patient has risk factors for seizures; 2. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy or cabazitaxel. Renewals: Renewals will be considered in patients who have not experienced disease progression while on enzalutamide therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 310 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 305, record 183, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Enzalutamide · DIN 02562677 Manufacturer: Apotex Inc.; listing date 2026-05-29 Health Canada: Marketed since 2026-03-30 · brand APO-ENZALUTAMIDE · ATC L02BB04 ENZALUTAMIDE · form Capsule · route Oral · ingredients ENZALUTAMIDE 40 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Enzalutamide: Formulary list price $7.30 per unit (the source does not state the unit; exact figure $7.2989). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02562677)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02562677). DIN 02562677: Apo-Enzalutamide Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 100000224; group id 156; item number 0267; lccId None; manufacturer id APX Source form: Cap; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $7.2989; ministry $7.2989 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02562677 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106553
Interchangeable products
Auro-Enzalutamide · DIN 02494736 · $7.2989 Jamp Enzalutamide · DIN 02515229 · $7.2989 Reddy-Enzalutamide · DIN 02558424 · $7.2989 Xtandi · DIN 02407329 · $7.2989
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02562677
Shortage record checked October 6, 2026

Auro-Enzalutamide · DIN 02494736 · 40 mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Xtandi; DOSAGE FORM/ STRENGTH: 40 mg capsule — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Updated: December 1, 2021 Initiation criteria for metastatic castration sensitive prostate cancer (mCSPC): For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on technetium-99m bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Castration sensitive as defined by the patient being treatment naïve to an ADT OR ADT initiated within the prior 6 months before start of therapy with enzalutamide OR ADT used in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more prior to start of enzalutamide; AND 4. Has not experienced disease progression with another an androgen receptor axis targeted therapy (ARAT) for castration sensitive prostate cancer; AND 5. Patient has good performance status. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) The following baseline levels are to be provided with the initial application; i) Number of metastatic lesions on bone scan and in soft tissues ii) Testosterone level iii) Baseline (pre-treatment) PSA level iv) Pre-treatment Gleason score (optional) 305 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have previously progressed on a second-generation androgen receptor inhibitor (e.g. apalutamide, enzalutamide, darolutamide) for prostate cancer will not be eligible for enzalutamide in mCSPC. The Ministry will fund only one of enzalutamide or apalutamide in patients with mCSPC. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Patients who progress on treatment with enzalutamide or apalutamide mCSPC will not be eligible for enzalutamide in the metastatic castration resistant setting. 4. Patients who are currently on a treatment regimen with an androgen receptor axis targeted therapy (e.g. abiraterone or a second-generation androgen receptor inhibitor) for prostate cancer, must meet the initiation criteria if they wish to switch to publicly funded enzalutamide for mCSPC. 5. Time limited funding consideration will be provided on a case-by case basis for those patients who are using docetaxel in combination with ADT as long as there has been no progression and the treatment regimen has not been used for more than 6 months. Approved Dosage: 160 mg administered orally once daily. Renewal Criteria: Renewals will be considered in patients until disease progression (i.e. PSA elevation in addition to radiographic disease progression, or PSA progression in addition to clinical symptoms associated with cancer progression), development of castration resistant disease, or experiencing unacceptable toxicity while on enzalutamide. Exclusion Criteria: (Patients meeting any of the following will not be funded.) 1. Patients who have previously experienced disease progression on enzalutamide or another ARI used in the setting of prostate cancer. 2. Patients who have risk factors for seizures 3. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 306 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation Criteria for high risk non-metastatic castration resistant prostate cancer (nmCRPC): For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) in patients who meet all the following criteria: 1. Patient using Xtandi in combination with androgen deprivation therapy (ADT); AND 2. Has no detectable distant metastases as determined by CT, MRI, or technetium-99m bone scan; AND 3. Patient has castration resistant disease based on meeting all the following indicia observed while on continuous ADT treatment or post orchiectomy: • Castrate serum testosterone levels: AND • Biochemical progression defined as Three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL; and 4. Patient is at high risk for developing metastatic disease based on a Prostate-specific antigen doubling time (PSADT) of less than or equal to 10 months during continuous ADT. 5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2. Approval Duration: 1 year Exclusion Criteria: 1. The patient received prior chemotherapy for the treatment of prostate cancer, unless it was in the adjuvant or neoadjuvant setting. 2. The patient has previously experienced disease progression on apalutamide or darolutamide used for prostate cancer. 3. The patient has risk factors for seizures. 307 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) Approved Dosage: 160mg administered orally once daily Notes: 1. The Ministry will fund only one second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, or enzalutamide) in patients with nmCRPC. 2. Patients who have progressed on enzalutamide in nmCRPC will not be eligible for enzalutamide in metastatic castration resistant prostate cancer (mCRPC). 3. Requests for enzalutamide in patients who have initiated another ARI therapy in the nmCRPC setting and who have not experienced disease progression will be considered on a case-by-case basis. Renewal Criteria: Renewals will be considered in patients without evidence of radiographic disease progression or unacceptable toxicity while on enzalutamide therapy. Approval Duration: 1 year 308 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation criteria for metastatic castration resistant prostate cancer (mCRPC): For the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients meeting the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on a bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Patient has castration resistant disease based on meeting the following indicia observed while on continuous ADT treatment or post orchiectomy: 4. Castrate serum testosterone levels; AND 5. Biochemical progression defined as three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL AND/OR radiographic progression of new or pre-existing disease as determined by the detection of 2 or more lesions on bone scan or presence of new soft tissue lesions by RECIST criteria; AND 6. Patient has progressed on a docetaxel-based chemotherapy OR Patient is using enzalutamide pre-docetaxel for metastatic castration resistant prostate cancer and has not previously experienced disease progression on enzalutamide or another second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide,) used for prostate cancer OR Patient is using enzalutamide pre-docetaxel for mCRPC and has not previously experienced disease progression on abiraterone used in mCRPC sequenced immediately prior to enzalutamide; AND 7. Patient has good performance status defined as an Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 2. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) 309 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have progressed on treatment with second generation androgen receptor inhibitors (e.g. apalutamide, enzalutamide, darolutamide) used in prior stages of prostate cancer will not be eligible for enzalutamide in the metastatic castration resistant setting. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Requests for enzalutamide in patients who initiated abiraterone therapy and who have not had disease progression while on abiraterone will be considered on a case-by- case basis. Exclusion criteria: (Patients meeting any of the following will not be funded) 1. The patient has risk factors for seizures; 2. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy or cabazitaxel. Renewals: Renewals will be considered in patients who have not experienced disease progression while on enzalutamide therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 310 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 305, record 183, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Enzalutamide · DIN 02494736 Manufacturer: Auro Pharma Inc.; listing date 2026-05-29 Health Canada: Marketed since 2026-03-30 · brand AURO-ENZALUTAMIDE · ATC L02BB04 ENZALUTAMIDE · form Capsule · route Oral · ingredients ENZALUTAMIDE 40 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Enzalutamide: Formulary list price $7.30 per unit (the source does not state the unit; exact figure $7.2989). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02494736)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02494736). DIN 02494736: Auro-Enzalutamide Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 100000224; group id 156; item number 0267; lccId None; manufacturer id AUR Source form: Cap; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $7.2989; ministry $7.2989 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02494736 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98471
Interchangeable products
Apo-Enzalutamide · DIN 02562677 · $7.2989 Jamp Enzalutamide · DIN 02515229 · $7.2989 Reddy-Enzalutamide · DIN 02558424 · $7.2989 Xtandi · DIN 02407329 · $7.2989
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02494736
Shortage record checked October 6, 2026

Jamp Enzalutamide · DIN 02515229 · 40 mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Xtandi; DOSAGE FORM/ STRENGTH: 40 mg capsule — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Updated: December 1, 2021 Initiation criteria for metastatic castration sensitive prostate cancer (mCSPC): For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on technetium-99m bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Castration sensitive as defined by the patient being treatment naïve to an ADT OR ADT initiated within the prior 6 months before start of therapy with enzalutamide OR ADT used in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more prior to start of enzalutamide; AND 4. Has not experienced disease progression with another an androgen receptor axis targeted therapy (ARAT) for castration sensitive prostate cancer; AND 5. Patient has good performance status. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) The following baseline levels are to be provided with the initial application; i) Number of metastatic lesions on bone scan and in soft tissues ii) Testosterone level iii) Baseline (pre-treatment) PSA level iv) Pre-treatment Gleason score (optional) 305 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have previously progressed on a second-generation androgen receptor inhibitor (e.g. apalutamide, enzalutamide, darolutamide) for prostate cancer will not be eligible for enzalutamide in mCSPC. The Ministry will fund only one of enzalutamide or apalutamide in patients with mCSPC. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Patients who progress on treatment with enzalutamide or apalutamide mCSPC will not be eligible for enzalutamide in the metastatic castration resistant setting. 4. Patients who are currently on a treatment regimen with an androgen receptor axis targeted therapy (e.g. abiraterone or a second-generation androgen receptor inhibitor) for prostate cancer, must meet the initiation criteria if they wish to switch to publicly funded enzalutamide for mCSPC. 5. Time limited funding consideration will be provided on a case-by case basis for those patients who are using docetaxel in combination with ADT as long as there has been no progression and the treatment regimen has not been used for more than 6 months. Approved Dosage: 160 mg administered orally once daily. Renewal Criteria: Renewals will be considered in patients until disease progression (i.e. PSA elevation in addition to radiographic disease progression, or PSA progression in addition to clinical symptoms associated with cancer progression), development of castration resistant disease, or experiencing unacceptable toxicity while on enzalutamide. Exclusion Criteria: (Patients meeting any of the following will not be funded.) 1. Patients who have previously experienced disease progression on enzalutamide or another ARI used in the setting of prostate cancer. 2. Patients who have risk factors for seizures 3. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 306 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation Criteria for high risk non-metastatic castration resistant prostate cancer (nmCRPC): For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) in patients who meet all the following criteria: 1. Patient using Xtandi in combination with androgen deprivation therapy (ADT); AND 2. Has no detectable distant metastases as determined by CT, MRI, or technetium-99m bone scan; AND 3. Patient has castration resistant disease based on meeting all the following indicia observed while on continuous ADT treatment or post orchiectomy: • Castrate serum testosterone levels: AND • Biochemical progression defined as Three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL; and 4. Patient is at high risk for developing metastatic disease based on a Prostate-specific antigen doubling time (PSADT) of less than or equal to 10 months during continuous ADT. 5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2. Approval Duration: 1 year Exclusion Criteria: 1. The patient received prior chemotherapy for the treatment of prostate cancer, unless it was in the adjuvant or neoadjuvant setting. 2. The patient has previously experienced disease progression on apalutamide or darolutamide used for prostate cancer. 3. The patient has risk factors for seizures. 307 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) Approved Dosage: 160mg administered orally once daily Notes: 1. The Ministry will fund only one second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, or enzalutamide) in patients with nmCRPC. 2. Patients who have progressed on enzalutamide in nmCRPC will not be eligible for enzalutamide in metastatic castration resistant prostate cancer (mCRPC). 3. Requests for enzalutamide in patients who have initiated another ARI therapy in the nmCRPC setting and who have not experienced disease progression will be considered on a case-by-case basis. Renewal Criteria: Renewals will be considered in patients without evidence of radiographic disease progression or unacceptable toxicity while on enzalutamide therapy. Approval Duration: 1 year 308 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation criteria for metastatic castration resistant prostate cancer (mCRPC): For the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients meeting the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on a bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Patient has castration resistant disease based on meeting the following indicia observed while on continuous ADT treatment or post orchiectomy: 4. Castrate serum testosterone levels; AND 5. Biochemical progression defined as three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL AND/OR radiographic progression of new or pre-existing disease as determined by the detection of 2 or more lesions on bone scan or presence of new soft tissue lesions by RECIST criteria; AND 6. Patient has progressed on a docetaxel-based chemotherapy OR Patient is using enzalutamide pre-docetaxel for metastatic castration resistant prostate cancer and has not previously experienced disease progression on enzalutamide or another second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide,) used for prostate cancer OR Patient is using enzalutamide pre-docetaxel for mCRPC and has not previously experienced disease progression on abiraterone used in mCRPC sequenced immediately prior to enzalutamide; AND 7. Patient has good performance status defined as an Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 2. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) 309 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have progressed on treatment with second generation androgen receptor inhibitors (e.g. apalutamide, enzalutamide, darolutamide) used in prior stages of prostate cancer will not be eligible for enzalutamide in the metastatic castration resistant setting. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Requests for enzalutamide in patients who initiated abiraterone therapy and who have not had disease progression while on abiraterone will be considered on a case-by- case basis. Exclusion criteria: (Patients meeting any of the following will not be funded) 1. The patient has risk factors for seizures; 2. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy or cabazitaxel. Renewals: Renewals will be considered in patients who have not experienced disease progression while on enzalutamide therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 310 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 305, record 183, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Enzalutamide · DIN 02515229 Manufacturer: Jamp Pharma Corporation; listing date 2026-03-31 Health Canada: Marketed since 2026-02-20 · brand JAMP ENZALUTAMIDE · ATC L02BB04 ENZALUTAMIDE · form Capsule · route Oral · ingredients ENZALUTAMIDE 40 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Enzalutamide: Formulary list price $7.30 per unit (the source does not state the unit; exact figure $7.2989). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02515229)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02515229). DIN 02515229: Jamp Enzalutamide Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 100000224; group id 156; item number 0267; lccId None; manufacturer id JPC Source form: Cap; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $7.2989; ministry $7.2989 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02515229 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100461
Interchangeable products
Apo-Enzalutamide · DIN 02562677 · $7.2989 Auro-Enzalutamide · DIN 02494736 · $7.2989 Reddy-Enzalutamide · DIN 02558424 · $7.2989 Xtandi · DIN 02407329 · $7.2989
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02515229
Shortage record checked October 6, 2026

Reddy-Enzalutamide · DIN 02558424 · 40 mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Xtandi; DOSAGE FORM/ STRENGTH: 40 mg capsule — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Updated: December 1, 2021 Initiation criteria for metastatic castration sensitive prostate cancer (mCSPC): For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on technetium-99m bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Castration sensitive as defined by the patient being treatment naïve to an ADT OR ADT initiated within the prior 6 months before start of therapy with enzalutamide OR ADT used in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more prior to start of enzalutamide; AND 4. Has not experienced disease progression with another an androgen receptor axis targeted therapy (ARAT) for castration sensitive prostate cancer; AND 5. Patient has good performance status. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) The following baseline levels are to be provided with the initial application; i) Number of metastatic lesions on bone scan and in soft tissues ii) Testosterone level iii) Baseline (pre-treatment) PSA level iv) Pre-treatment Gleason score (optional) 305 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have previously progressed on a second-generation androgen receptor inhibitor (e.g. apalutamide, enzalutamide, darolutamide) for prostate cancer will not be eligible for enzalutamide in mCSPC. The Ministry will fund only one of enzalutamide or apalutamide in patients with mCSPC. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Patients who progress on treatment with enzalutamide or apalutamide mCSPC will not be eligible for enzalutamide in the metastatic castration resistant setting. 4. Patients who are currently on a treatment regimen with an androgen receptor axis targeted therapy (e.g. abiraterone or a second-generation androgen receptor inhibitor) for prostate cancer, must meet the initiation criteria if they wish to switch to publicly funded enzalutamide for mCSPC. 5. Time limited funding consideration will be provided on a case-by case basis for those patients who are using docetaxel in combination with ADT as long as there has been no progression and the treatment regimen has not been used for more than 6 months. Approved Dosage: 160 mg administered orally once daily. Renewal Criteria: Renewals will be considered in patients until disease progression (i.e. PSA elevation in addition to radiographic disease progression, or PSA progression in addition to clinical symptoms associated with cancer progression), development of castration resistant disease, or experiencing unacceptable toxicity while on enzalutamide. Exclusion Criteria: (Patients meeting any of the following will not be funded.) 1. Patients who have previously experienced disease progression on enzalutamide or another ARI used in the setting of prostate cancer. 2. Patients who have risk factors for seizures 3. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 306 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation Criteria for high risk non-metastatic castration resistant prostate cancer (nmCRPC): For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) in patients who meet all the following criteria: 1. Patient using Xtandi in combination with androgen deprivation therapy (ADT); AND 2. Has no detectable distant metastases as determined by CT, MRI, or technetium-99m bone scan; AND 3. Patient has castration resistant disease based on meeting all the following indicia observed while on continuous ADT treatment or post orchiectomy: • Castrate serum testosterone levels: AND • Biochemical progression defined as Three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL; and 4. Patient is at high risk for developing metastatic disease based on a Prostate-specific antigen doubling time (PSADT) of less than or equal to 10 months during continuous ADT. 5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2. Approval Duration: 1 year Exclusion Criteria: 1. The patient received prior chemotherapy for the treatment of prostate cancer, unless it was in the adjuvant or neoadjuvant setting. 2. The patient has previously experienced disease progression on apalutamide or darolutamide used for prostate cancer. 3. The patient has risk factors for seizures. 307 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) Approved Dosage: 160mg administered orally once daily Notes: 1. The Ministry will fund only one second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, or enzalutamide) in patients with nmCRPC. 2. Patients who have progressed on enzalutamide in nmCRPC will not be eligible for enzalutamide in metastatic castration resistant prostate cancer (mCRPC). 3. Requests for enzalutamide in patients who have initiated another ARI therapy in the nmCRPC setting and who have not experienced disease progression will be considered on a case-by-case basis. Renewal Criteria: Renewals will be considered in patients without evidence of radiographic disease progression or unacceptable toxicity while on enzalutamide therapy. Approval Duration: 1 year 308 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation criteria for metastatic castration resistant prostate cancer (mCRPC): For the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients meeting the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on a bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Patient has castration resistant disease based on meeting the following indicia observed while on continuous ADT treatment or post orchiectomy: 4. Castrate serum testosterone levels; AND 5. Biochemical progression defined as three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL AND/OR radiographic progression of new or pre-existing disease as determined by the detection of 2 or more lesions on bone scan or presence of new soft tissue lesions by RECIST criteria; AND 6. Patient has progressed on a docetaxel-based chemotherapy OR Patient is using enzalutamide pre-docetaxel for metastatic castration resistant prostate cancer and has not previously experienced disease progression on enzalutamide or another second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide,) used for prostate cancer OR Patient is using enzalutamide pre-docetaxel for mCRPC and has not previously experienced disease progression on abiraterone used in mCRPC sequenced immediately prior to enzalutamide; AND 7. Patient has good performance status defined as an Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 2. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) 309 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have progressed on treatment with second generation androgen receptor inhibitors (e.g. apalutamide, enzalutamide, darolutamide) used in prior stages of prostate cancer will not be eligible for enzalutamide in the metastatic castration resistant setting. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Requests for enzalutamide in patients who initiated abiraterone therapy and who have not had disease progression while on abiraterone will be considered on a case-by- case basis. Exclusion criteria: (Patients meeting any of the following will not be funded) 1. The patient has risk factors for seizures; 2. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy or cabazitaxel. Renewals: Renewals will be considered in patients who have not experienced disease progression while on enzalutamide therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 310 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 305, record 183, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Reddy-Enzalutamide · DIN 02558424 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2026-05-29 Health Canada: Marketed since 2026-03-30 · brand REDDY-ENZALUTAMIDE · ATC L02BB04 ENZALUTAMIDE · form Capsule · route Oral · ingredients ENZALUTAMIDE 40 MG · company Dr reddy's laboratories ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Reddy-Enzalutamide: Formulary list price $7.30 per unit (the source does not state the unit; exact figure $7.2989). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02558424)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02558424). DIN 02558424: Reddy-Enzalutamide Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 100000224; group id 156; item number 0267; lccId None; manufacturer id DRR Source form: Cap; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $7.2989; ministry $7.2989 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02558424 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106167
Interchangeable products
Apo-Enzalutamide · DIN 02562677 · $7.2989 Auro-Enzalutamide · DIN 02494736 · $7.2989 Jamp Enzalutamide · DIN 02515229 · $7.2989 Xtandi · DIN 02407329 · $7.2989
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02558424
Shortage record checked October 6, 2026

Xtandi · DIN 02407329 · 40 mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Patient paysExceptional Access application required; if approved, ODB 65 and over pays as shown above

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Updated: December 1, 2021 Initiation criteria for metastatic castration sensitive prostate cancer (mCSPC): For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on technetium-99m bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Castration sensitive as defined by the patient being treatment naïve to an ADT OR ADT initiated within the prior 6 months before start of therapy with enzalutamide OR ADT used in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more prior to start of enzalutamide; AND 4. Has not experienced disease progression with another an androgen receptor axis targeted therapy (ARAT) for castration sensitive prostate cancer; AND 5. Patient has good performance status. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) The following baseline levels are to be provided with the initial application; i) Number of metastatic lesions on bone scan and in soft tissues ii) Testosterone level iii) Baseline (pre-treatment) PSA level iv) Pre-treatment Gleason score (optional) 305 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have previously progressed on a second-generation androgen receptor inhibitor (e.g. apalutamide, enzalutamide, darolutamide) for prostate cancer will not be eligible for enzalutamide in mCSPC. The Ministry will fund only one of enzalutamide or apalutamide in patients with mCSPC. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Patients who progress on treatment with enzalutamide or apalutamide mCSPC will not be eligible for enzalutamide in the metastatic castration resistant setting. 4. Patients who are currently on a treatment regimen with an androgen receptor axis targeted therapy (e.g. abiraterone or a second-generation androgen receptor inhibitor) for prostate cancer, must meet the initiation criteria if they wish to switch to publicly funded enzalutamide for mCSPC. 5. Time limited funding consideration will be provided on a case-by case basis for those patients who are using docetaxel in combination with ADT as long as there has been no progression and the treatment regimen has not been used for more than 6 months. Approved Dosage: 160 mg administered orally once daily. Renewal Criteria: Renewals will be considered in patients until disease progression (i.e. PSA elevation in addition to radiographic disease progression, or PSA progression in addition to clinical symptoms associated with cancer progression), development of castration resistant disease, or experiencing unacceptable toxicity while on enzalutamide. Exclusion Criteria: (Patients meeting any of the following will not be funded.) 1. Patients who have previously experienced disease progression on enzalutamide or another ARI used in the setting of prostate cancer. 2. Patients who have risk factors for seizures 3. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 306 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation Criteria for high risk non-metastatic castration resistant prostate cancer (nmCRPC): For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) in patients who meet all the following criteria: 1. Patient using Xtandi in combination with androgen deprivation therapy (ADT); AND 2. Has no detectable distant metastases as determined by CT, MRI, or technetium-99m bone scan; AND 3. Patient has castration resistant disease based on meeting all the following indicia observed while on continuous ADT treatment or post orchiectomy: • Castrate serum testosterone levels: AND • Biochemical progression defined as Three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL; and 4. Patient is at high risk for developing metastatic disease based on a Prostate-specific antigen doubling time (PSADT) of less than or equal to 10 months during continuous ADT. 5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2. Approval Duration: 1 year Exclusion Criteria: 1. The patient received prior chemotherapy for the treatment of prostate cancer, unless it was in the adjuvant or neoadjuvant setting. 2. The patient has previously experienced disease progression on apalutamide or darolutamide used for prostate cancer. 3. The patient has risk factors for seizures. 307 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) Approved Dosage: 160mg administered orally once daily Notes: 1. The Ministry will fund only one second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, or enzalutamide) in patients with nmCRPC. 2. Patients who have progressed on enzalutamide in nmCRPC will not be eligible for enzalutamide in metastatic castration resistant prostate cancer (mCRPC). 3. Requests for enzalutamide in patients who have initiated another ARI therapy in the nmCRPC setting and who have not experienced disease progression will be considered on a case-by-case basis. Renewal Criteria: Renewals will be considered in patients without evidence of radiographic disease progression or unacceptable toxicity while on enzalutamide therapy. Approval Duration: 1 year 308 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Initiation criteria for metastatic castration resistant prostate cancer (mCRPC): For the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients meeting the following criteria: 1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND 2. Metastatic lesions detected on a bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND 3. Patient has castration resistant disease based on meeting the following indicia observed while on continuous ADT treatment or post orchiectomy: 4. Castrate serum testosterone levels; AND 5. Biochemical progression defined as three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL AND/OR radiographic progression of new or pre-existing disease as determined by the detection of 2 or more lesions on bone scan or presence of new soft tissue lesions by RECIST criteria; AND 6. Patient has progressed on a docetaxel-based chemotherapy OR Patient is using enzalutamide pre-docetaxel for metastatic castration resistant prostate cancer and has not previously experienced disease progression on enzalutamide or another second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide,) used for prostate cancer OR Patient is using enzalutamide pre-docetaxel for mCRPC and has not previously experienced disease progression on abiraterone used in mCRPC sequenced immediately prior to enzalutamide; AND 7. Patient has good performance status defined as an Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 2. 1ADT is not required for patients with bilateral orchiectomy Definitions for the purpose of the EAP funding criteria: ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix) ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide) ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide) 309 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Notes: 1. Patients who have progressed on treatment with second generation androgen receptor inhibitors (e.g. apalutamide, enzalutamide, darolutamide) used in prior stages of prostate cancer will not be eligible for enzalutamide in the metastatic castration resistant setting. 2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis. 3. Requests for enzalutamide in patients who initiated abiraterone therapy and who have not had disease progression while on abiraterone will be considered on a case-by- case basis. Exclusion criteria: (Patients meeting any of the following will not be funded) 1. The patient has risk factors for seizures; 2. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy or cabazitaxel. Renewals: Renewals will be considered in patients who have not experienced disease progression while on enzalutamide therapy. Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year 310 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 305, record 183, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Xtandi · DIN 02407329 Manufacturer: Astellas Pharma Canada Inc.; listing date 2026-03-31 Health Canada: Marketed since 2013-06-07 · brand XTANDI · ATC L02BB04 ENZALUTAMIDE · form Capsule · route Oral · ingredients ENZALUTAMIDE 40 MG · company Astellas pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02407329)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02407329). DIN 02407329: Xtandi Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 100000224; group id 156; item number 0267; lccId None; manufacturer id ASE Source form: Cap; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $29.1954; ministry $7.2989 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02407329 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89203
Interchangeable products
Apo-Enzalutamide · DIN 02562677 · $7.2989 Auro-Enzalutamide · DIN 02494736 · $7.2989 Jamp Enzalutamide · DIN 02515229 · $7.2989 Reddy-Enzalutamide · DIN 02558424 · $7.2989
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02407329
Shortage record checked October 6, 2026

Other products in the same Health Canada class (L02B, L02BB): coverage varies; not interchangeable

  • Bicalutamide (Casodex): general benefit, not a benefit
  • Flutamide (Euflex): general benefit, not a benefit
  • Abiraterone (Zytiga): general benefit
  • Anastrozole (Arimidex): general benefit
  • Degarelix (Firmagon): general benefit
  • Exemestane (Aromasin): general benefit

3 more in the class list below

Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ANASTROZOLE

· 18 products · General benefit · strengths: 1mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

TAMOXIFEN CITRATE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Xtandi® (enzalutamide) is indicated for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR) (see 14 CLINICAL TRIALS). Xtandi® (enzalutamide) is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). Xtandi® (enzalutamide) is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Xtandi has not been studied in patients with nmCRPC at low risk of developing metastatic disease (see 14 CLINICAL TRIALS). The benefit and risk profile in these patients is unknown. Xtandi® (enzalutamide) is indicated in the setting of medical or surgical castration for the treatment of metastatic castration-resistant prostate cancer (CRPC) in patients who: • are chemotherapy-naïve with asymptomatic or mildly symptomatic disease after failure of androgen deprivation therapy. • have received docetaxel therapy. 1.1 Pediatrics The safety and efficacy of Xtandi® has not been established for patients less than 18 years of ag… https://pdf.hres.ca/dpd_pm/00083290.PDF PM date: 2026-01-26 Source product: XTANDI; DIN 02407329; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated October 05, 2026

Enzalutamide (Xtandi)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria:

Ministry criteria corpus 2025-01-01; page 305

Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule Updated: December 1, 2021
Initiation criteria for metastatic castration sensitive prostate cancer (mCSPC):
For the treatment metastatic castration sensitive prostate cancer (mCSPC) in patients who meet all of the following criteria:
1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND
2. Metastatic lesions detected on technetium-99m bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND
3. Castration sensitive as defined by the patient being treatment naïve to an ADT OR ADT initiated within the prior 6 months before start of therapy with enzalutamide OR ADT used in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more prior to start of enzalutamide; AND
4. Has not experienced disease progression with another an androgen receptor axis targeted therapy (ARAT) for castration sensitive prostate cancer; AND
5. Patient has good performance status. 1ADT is not required for patients with bilateral orchiectomy
Definitions for the purpose of the EAP funding criteria:
ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix)
ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide)
ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide)
The following baseline levels are to be provided with the initial application;
i) Number of metastatic lesions on bone scan and in soft tissues
ii) Testosterone level
iii) Baseline (pre-treatment) PSA level
iv) Pre-treatment Gleason score (optional)
305 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule
Notes:
1. Patients who have previously progressed on a second-generation androgen receptor inhibitor (e.g. apalutamide, enzalutamide, darolutamide) for prostate cancer will not be eligible for enzalutamide in mCSPC. The Ministry will fund only one of enzalutamide or apalutamide in patients with mCSPC.
2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis.
3. Patients who progress on treatment with enzalutamide or apalutamide mCSPC will not be eligible for enzalutamide in the metastatic castration resistant setting.
4. Patients who are currently on a treatment regimen with an androgen receptor axis targeted therapy (e.g. abiraterone or a second-generation androgen receptor inhibitor) for prostate cancer, must meet the initiation criteria if they wish to switch to publicly funded enzalutamide for mCSPC.
5. Time limited funding consideration will be provided on a case-by case basis for those patients who are using docetaxel in combination with ADT as long as there has been no progression and the treatment regimen has not been used for more than 6 months.
Approved Dosage: 160 mg administered orally once daily.
Renewal Criteria:
Renewals will be considered in patients until disease progression (i.e. PSA elevation in addition to radiographic disease progression, or PSA progression in addition to clinical symptoms associated with cancer progression), development of castration resistant disease, or experiencing unacceptable toxicity while on enzalutamide.
Exclusion Criteria: (Patients meeting any of the following will not be funded.)
1. Patients who have previously experienced disease progression on enzalutamide or another ARI used in the setting of prostate cancer.
2. Patients who have risk factors for seizures
3. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy.
Approved Dosage for Initials and Renewals:160 mg administered orally once daily. Duration of initial and renewal approvals: 1 year
306 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule
Initiation Criteria for high risk non-metastatic castration resistant prostate cancer (nmCRPC):
For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) in patients who meet all the following criteria:
1. Patient using Xtandi in combination with androgen deprivation therapy (ADT); AND
2. Has no detectable distant metastases as determined by CT, MRI, or technetium-99m bone scan; AND
3. Patient has castration resistant disease based on meeting all the following indicia observed while on continuous ADT treatment or post orchiectomy:
• Castrate serum testosterone levels: AND
• Biochemical progression defined as Three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL; and
4. Patient is at high risk for developing metastatic disease based on a Prostate-specific antigen doubling time (PSADT) of less than or equal to 10 months during continuous ADT.
5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2.
Approval Duration: 1 year
Exclusion Criteria:
1. The patient received prior chemotherapy for the treatment of prostate cancer, unless it was in the adjuvant or neoadjuvant setting.
2. The patient has previously experienced disease progression on apalutamide or darolutamide used for prostate cancer.
3. The patient has risk factors for seizures.
307 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule
Definitions for the purpose of the EAP funding criteria:
ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix)
ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide)
Approved Dosage: 160mg administered orally once daily
Notes:
1. The Ministry will fund only one second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, or enzalutamide) in patients with nmCRPC.
2. Patients who have progressed on enzalutamide in nmCRPC will not be eligible for enzalutamide in metastatic castration resistant prostate cancer (mCRPC).
3. Requests for enzalutamide in patients who have initiated another ARI therapy in the nmCRPC setting and who have not experienced disease progression will be considered on a case-by-case basis.
Renewal Criteria:
Renewals will be considered in patients without evidence of radiographic disease progression or unacceptable toxicity while on enzalutamide therapy.
Approval Duration: 1 year
308 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule
Initiation criteria for metastatic castration resistant prostate cancer (mCRPC):
For the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients meeting the following criteria:
1. Enzalutamide is used in combination with androgen deprivation therapy (ADT)1; AND
2. Metastatic lesions detected on a bone scan, computed tomography (CT), and/or magnetic resonance imaging (MRI); AND
3. Patient has castration resistant disease based on meeting the following indicia observed while on continuous ADT treatment or post orchiectomy:
4. Castrate serum testosterone levels; AND
5. Biochemical progression defined as three (3) prostate-specific antigen (PSA) rises at least 1 week apart, with the last PSA greater than 2ng/mL AND/OR radiographic progression of new or pre-existing disease as determined by the detection of 2 or more lesions on bone scan or presence of new soft tissue lesions by RECIST criteria; AND
6. Patient has progressed on a docetaxel-based chemotherapy OR Patient is using enzalutamide pre-docetaxel for metastatic castration resistant prostate cancer and has not previously experienced disease progression on enzalutamide or another second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide,) used for prostate cancer OR Patient is using enzalutamide pre-docetaxel for mCRPC and has not previously experienced disease progression on abiraterone used in mCRPC sequenced immediately prior to enzalutamide; AND
7. Patient has good performance status defined as an Eastern Cooperative Oncology Group (ECOG) Performance status less than or equal to 2. 1ADT is not required for patients with bilateral orchiectomy
Definitions for the purpose of the EAP funding criteria:
ADT – A first generation androgen deprivation therapy (e.g. goserelin, leuprolide, triptorelin, buserelin, degarelix)
ARI- A second generation androgen receptor inhibitor (e.g. apalutamide, darolutamide, enzalutamide)
ARAT- An androgen receptor axis targeted therapy (e.g. abiraterone, apalutamide, darolutamide, enzalutamide)
309 Enzalutamide Brand(s): Xtandi DOSAGE FORM/STRENGTH: 40 mg capsule
Notes:
1. Patients who have progressed on treatment with second generation androgen receptor inhibitors (e.g. apalutamide, enzalutamide, darolutamide) used in prior stages of prostate cancer will not be eligible for enzalutamide in the metastatic castration resistant setting.
2. Patients treated with apalutamide or darolutamide as part of a clinical trial may be eligible for enzalutamide and will be considered on a case-by-case basis.
3. Requests for enzalutamide in patients who initiated abiraterone therapy and who have not had disease progression while on abiraterone will be considered on a case-by- case basis.
Exclusion criteria: (Patients meeting any of the following will not be funded)
1. The patient has risk factors for seizures;
2. Enzalutamide will not be funded as combination therapy with another androgen receptor axis targeted therapy or cabazitaxel.
Renewals:
Renewals will be considered in patients who have not experienced disease progression while on enzalutamide therapy.
Approved Dosage for Initials and Renewals:160 mg administered orally once daily.
Duration of initial and renewal approvals: 1 year
310

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.

Other review policies

For Apo-Enzalutamide, Auro-Enzalutamide, Jamp Enzalutamide, Reddy-Enzalutamide: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026